ArchiveMay 2013

DMF or BG12 launch in US defies analysts predictions

Matthew Herper. Biogen Idec’s MS Drug Launch Is Going Amazingly Well. These Two Graphs Prove It. PHARMA & HEALTHCARE . 5/29/2013 @ 11:16AM  Sales of the dimethyl fumarate (Tecfidera) are destroying what were already very high expectations. Mark Schoenebaum at International Strategy & Investment Group noted on Tuesday that according to data from IMS Health...

Osteopontin a marker of MS activity

Szalardy L, Zadori D, Simu M, Bencsik K, Vecsei L, Klivenyi P. Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis-osteopontin as a potential marker of clinical severity. J Neurol Sci. 2013 May 21. doi:pii: S0022-510X(13)00204-9. 10.1016/ j.jns.2013.04.024. [Epub ahead of print] Biomarkers capable of predicting the clinical course and...

Pilatates and Aquatic Exercise aids balance

Marandi SM, Nejad VS, Shanazari Z, Zolaktaf V. A Comparison of 12 Weeks of Pilates and Aquatic Training on the Dynamic Balance of Women with Mulitple Sclerosis. Int J Prev Med. 2013 Apr;4(Suppl 1):S110-S117. BACKGROUND: Multiple Sclerosis (MS) is a disabling chronic disease of the nervous system in which the myelin system of the central nervous system is deteriorated. The objective of this...

Removing damaging immune responses from the brain saves nerves

Epub: Axelsson et al. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.Mult Scler. 2013 May 23.  BACKGROUND:In progressive multiple sclerosis (PMS), disease-modifying therapies have not been shown to reduce disability progression. OBJECTIVE:The impact from immunosuppressive therapy in PMS was explored by analyzing cerebrospinal fluid (CSF) biomarkers of...

T cells in MS lesions

Fischer MT, Wimmer I, Höftberger R, Gerlach S, Haider L, Zrzavy T, Hametner S, Mahad D, Binder CJ, Krumbholz M, Bauer J, Bradl M, Lassmann H. Disease-specific molecular events in cortical multiple sclerosis lesions. Brain. 2013 May 17. [Epub ahead of print] Cortical lesions constitute an important part of multiple sclerosis pathology. Although inflammation appears to play a role in their...

MS lesions formation

“This highly technical paper explains that the migration of white blood cells into the brain and spinal cord of MSers is controlled by a protein that activates the production of enzymes that white cells use to tunnel their way into the brain and spinal cord tissues. By blocking this regulator, with a drug, you could potentially block migration of white cells into the brain and...

Damaging Antibodies they are not all against myelin

Lindner M, Ng JK, Hochmeister S, Meinl E, Linington C. Neurofascin 186 specific autoantibodies induce axonal injury and exacerbate disease severity in experimental autoimmune encephalomyelitis. Exp Neurol. 2013 May 17. doi:pii: S0014-4886(13)00151-9. 10. Axonal injury is considered the major cause of chronic disability in multiple sclerosis (MS) patients, however the mechanisms behind remain...

Actions and side effects of first-line injectables

Epub: Gobbi et al. Swiss Analysis of Multiple Sclerosis: A Multicenter, Non-Interventional, Retrospective Cohort Study of Disease-Modifying Therapies. Eur Neurol. 2013 May;70(1):35-41.  Background: There is a scarcity of reports comparing efficacy and tolerability of the multiple sclerosis (MS) disease-modifying therapies [DMTs; intramuscular interferon-β1a (IM IFNβ-1a), subcutaneous...

Less blood flow for Lesions?

Epub: Juurlink BH. The Evidence for Hypoperfusion as a Factor in Multiple Sclerosis Lesion Development. Mult Scler Int. 2013;2013:598093. The evidence that hypoxia is a precipitating factor in causing early MS lesions includes increased protein levels of hypoxia-inducible factor-1α; presence of the D-110 hypoxia-inducible protein; increased expression of hypoxia-inducible genes in lesions as...

Translate

Categories

Recent Posts

Recent Comments

Archives